Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Heinrich MC, Blay JY, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg JR, Jones RL, Kang YK, Razak AA, Trent J, Attia S, Le Cesne A, Boye K, Goldstein D, Sánchez C, Siontis BL, Cox P, Davis E, Sherman ML, Ruiz-Soto R, Bauer S

Open source

DOI: 10.1200/jco-24-02818
Published: 2025 Jul 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-02818,
  title = {Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.},
  author = {Heinrich MC and Blay JY and Gelderblom H and George S and Schöffski P and von Mehren M and Zalcberg JR and Jones RL and Kang YK and Razak AA and Trent J and Attia S and Le Cesne A and Boye K and Goldstein D and Sánchez C and Siontis BL and Cox P and Davis E and Sherman ML and Ruiz-Soto R and Bauer S},
  year = {2025},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-24-02818},
  url = {https://doi.org/10.1200/jco-24-02818}
}

RIS

TY  - JOUR
TI  - Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
AU  - Heinrich MC
AU  - Blay JY
AU  - Gelderblom H
AU  - George S
AU  - Schöffski P
AU  - von Mehren M
AU  - Zalcberg JR
AU  - Jones RL
AU  - Kang YK
AU  - Razak AA
AU  - Trent J
AU  - Attia S
AU  - Le Cesne A
AU  - Boye K
AU  - Goldstein D
AU  - Sánchez C
AU  - Siontis BL
AU  - Cox P
AU  - Davis E
AU  - Sherman ML
AU  - Ruiz-Soto R
AU  - Bauer S
PY  - 2025
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-24-02818
UR  - https://doi.org/10.1200/jco-24-02818
ER  -

APA

MC, H., JY, B., H, G., S, G., P, S., M, V. M., JR, Z., RL, J., YK, K., AA, R., J, T., S, A., A, L. C., K, B., D, G., C, S., BL, S., P, C., E, D., ML, S., R, R., & S, B. (2025). Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-24-02818

Source records

pubmed · retrieved 2026-09-27T08:50:03.128Z